CytoNiche
华龛生物
CytoNiche (华龛生物) is a Beijing-based biotech company specializing in 3D cell "smart manufacturing" technology. Founded in 2018 by a research team led by Professor Yanan Du from Tsinghua University's School of Medicine, the company has developed core 3D microcarrier technology to industrialize scalable cell production for applications including cell therapy . Liu Wei serves as co-founder and CEO , while Du remains chief scientist .
The company raised nearly RMB 300 million in a Series B round in early 2022, co-led by Gaorong Ventures, CICC Qide Fund, and CICC Qiyuan National Emerging Industry Venture Capital Fund, with follow-on from Sinovac and China National Biotec Group . In September 2025, CytoNiche closed a Series B+ round of several hundred million RMB backed by a consortium of Beijing government-guided funds and institutional investors including Beijing Medical and Health Industry Investment Fund and CMB International, with Gaorong Ventures continuing its support .
AI-generated — may contain errors, please verify.
Coverage
3D Cell Manufacturing Platform Huaxin Biotech Closes Series B+ Round to Accelerate Cell Therapy Commercialization for Global Clients
Ushering in the 2.0 era of cell-based industrialization.
Consumer/Medical Companies Launch New Products, Advanced Tech Market Share and Capacity Advance Further | Rongbao · November
Explore industry demand, and build solid R&D capabilities.
Global SaaS, New Brands, and Biopharma Companies Close New Funding Rounds | Rongbao · February
The vitality of spring.
Viva Biotech Completes Nearly RMB 300 Million Series B Funding Round to Accelerate Industrialization of 3D Cell "Smart Manufacturing"
Gaorong Ventures co-led the round.
